Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Divergence

Divergence

Our grapevine has revealed one or two small rumblings by biotech companies thinking about responding to their low share prices by buying back stock.

The appeal is the ability to buy back shares at prices a fraction of what they were when the companies went public - prices shareholders and companies alike may see as grossly unfair - while, one hopes, propping up prices at the same time.

However, with cash so dear, we wondered what rationale could drive management to donate blood for the sake of even the shareholders. With this in mind, we checked out a couple of companies that already have pursued the repurchase route.

Emisphere Technologies Inc. in May announced that it would

Read the full 1158 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE